# MAVS

## Overview
MAVS (mitochondrial antiviral signaling protein) is a gene that encodes a critical adaptor protein involved in the innate immune response to viral infections. The MAVS protein is anchored to the outer mitochondrial membrane and plays a pivotal role in the RIG-I-like receptor (RLR) signaling pathway. Upon detection of viral RNA by cytosolic receptors such as RIG-I and MDA5, MAVS facilitates the activation of transcription factors NF-κB and IRF3, leading to the production of type I interferons and pro-inflammatory cytokines, which are essential for antiviral defense (Seth2005Identification; Belgnaoui2011Orchestrating). The protein is characterized by an N-terminal caspase recruitment domain (CARD), a proline-rich region, and a C-terminal transmembrane domain, which is crucial for its mitochondrial localization and function (Seth2005Identification; Ren2020Regulation). MAVS is regulated through various post-translational modifications and protein interactions to ensure a balanced immune response, preventing excessive inflammation that could lead to cellular damage (Jacobs2014Regulation; Ren2020Regulation).

## Structure
MAVS (mitochondrial antiviral signaling protein) is a crucial component of the innate immune response, anchored to the outer mitochondrial membrane. The protein is characterized by several distinct domains: an N-terminal CARD-like domain, a proline-rich region, and a C-terminal transmembrane domain. The CARD-like domain is essential for MAVS signaling, as its deletion impairs the protein's ability to activate IFN-β and NF-κB, highlighting its critical role in antiviral signaling (Seth2005Identification). This domain is evolutionarily conserved and necessary for the interaction with other signaling proteins (Seth2005Identification).

The C-terminal transmembrane domain is responsible for targeting MAVS to the mitochondria, and its absence results in the protein becoming cytosolic, which disrupts its function (Seth2005Identification). MAVS forms filamentous structures upon activation, which are crucial for its signaling capabilities. These filaments are formed by the CARD domains assembling into helical structures, facilitating the recruitment of downstream signaling molecules (Jiang2019Structural).

Post-translational modifications, such as ubiquitination, play a role in regulating MAVS activity, promoting its aggregation and activation (Jiang2019Structural). MAVS also has splice variant isoforms, which may influence its function and localization, although specific details on these variants are not extensively covered in the provided context.

## Function
Mitochondrial antiviral signaling protein (MAVS) is a critical component of the innate immune response, primarily involved in the detection and response to viral infections. Located on the outer membrane of mitochondria, MAVS acts as an adaptor protein in the RIG-I-like receptor (RLR) signaling pathway. Upon recognition of viral RNA by cytosolic pattern recognition receptors such as RIG-I and MDA5, MAVS facilitates the activation of transcription factors NF-κB and IRF3, leading to the production of type I interferons and pro-inflammatory cytokines, which are essential for antiviral defense (Seth2005Identification; Belgnaoui2011Orchestrating).

MAVS contains an N-terminal caspase recruitment domain (CARD), a proline-rich region, and a C-terminal transmembrane domain that anchors it to the mitochondrial membrane. This localization is crucial for its function, as it allows MAVS to form prion-like aggregates necessary for its signaling activity (Seth2005Identification; Ren2020Regulation). The mitochondrial membrane potential is also essential for MAVS-mediated signaling, as it supports the structural rearrangement of the MAVS complex, facilitating a rapid antiviral response (Koshiba2011Mitochondrial).

MAVS is regulated through various mechanisms, including ubiquitination and interactions with other proteins, to prevent excessive immune responses that could lead to cellular damage (Jacobs2014Regulation; Ren2020Regulation).

## Clinical Significance
Mutations and alterations in the MAVS gene are implicated in various diseases, particularly autoimmune disorders and cancers. In systemic lupus erythematosus (SLE), MAVS aggregation is associated with increased levels of type I interferon (IFN-I), contributing to the disease's pathogenesis. This aggregation is linked to the down-regulation of MAVS-regulatory proteins, leading to impaired degradation and persistent activation of the IFN-I pathway (Shao2016Prion‐like). A single-nucleotide polymorphism (SNP) in MAVS, C79F, is associated with reduced IFN-I levels and milder SLE symptoms, suggesting a protective role against oxidative stress-induced MAVS activation (Buskiewicz2016Reactive).

In ovarian cancer, high MAVS expression correlates with poor prognosis, including lower overall survival and disease-free survival rates. MAVS expression is linked to advanced clinical features and may influence immune cell infiltration, affecting the tumor microenvironment and response to chemotherapy (Chen2021An). MAVS also plays a role in cardiac function, where its deletion leads to impaired energy metabolism and mitochondrial dysfunction, contributing to cardiac dysfunction (Wang2022Reduced). These findings highlight the clinical significance of MAVS in various diseases, emphasizing its potential as a therapeutic target.

## Interactions
MAVS (mitochondrial antiviral signaling protein) is involved in several critical protein-protein interactions that facilitate its role in antiviral signaling. MAVS interacts directly with RIG-I, a cytosolic receptor that recognizes viral RNA, leading to MAVS oligomerization at the mitochondrial membrane. This interaction is essential for the activation of transcription factors IRF3 and NF-κB, which are crucial for the antiviral response (Baril2009MAVS).

MAVS also forms complexes with TRAF proteins, including TRAF2, TRAF5, and TRAF6, which are recruited through specific TRAF-binding motifs on MAVS. These interactions are vital for the downstream activation of IRF3 and NF-κB, promoting the expression of antiviral genes (Liu2013MAVS).

The transmembrane (TM) domain of MAVS is critical for its oligomerization, a process necessary for its signaling function. Specific residues within the TM domain, such as W517, A521, G524, and V528, are essential for MAVS dimer formation (Baril2009MAVS).

MAVS is regulated by interactions with other proteins, such as Tom70, which enhances IFNβ induction, and NLRX1, which acts as a negative regulator by disrupting MAVS interactions with upstream partners (Jacobs2013Mechanisms). MAVS also interacts with COX5B, which represses reactive oxygen species and RLR signaling, thereby modulating MAVS-mediated antiviral signaling (Jacobs2013Mechanisms).


## References


[1. (Shao2016Prion‐like) Wen‐Hai Shao, Daniel H. Shu, Yuxuan Zhen, Brendan Hilliard, Stephen O. Priest, Matteo Cesaroni, Jenny P.‐Y. Ting, and Philip L. Cohen. Prion‐like aggregation of mitochondrial antiviral signaling protein in lupus patients is associated with increased levels of type i interferon. Arthritis &amp; Rheumatology, 68(11):2697–2707, October 2016. URL: http://dx.doi.org/10.1002/art.39733, doi:10.1002/art.39733. This article has 60 citations.](https://doi.org/10.1002/art.39733)

[2. (Seth2005Identification) Rashu B. Seth, Lijun Sun, Chee-Kwee Ea, and Zhijian J. Chen. Identification and characterization of mavs, a mitochondrial antiviral signaling protein that activates nf-κb and irf3. Cell, 122(5):669–682, September 2005. URL: http://dx.doi.org/10.1016/j.cell.2005.08.012, doi:10.1016/j.cell.2005.08.012. This article has 2676 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cell.2005.08.012)

[3. (Liu2013MAVS) Siqi Liu, Jueqi Chen, Xin Cai, Jiaxi Wu, Xiang Chen, You-Tong Wu, Lijun Sun, and Zhijian J Chen. Mavs recruits multiple ubiquitin e3 ligases to activate antiviral signaling cascades. eLife, August 2013. URL: http://dx.doi.org/10.7554/elife.00785, doi:10.7554/elife.00785. This article has 271 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.00785)

[4. (Jacobs2014Regulation) Jana L. Jacobs, Jianzhong Zhu, Saumendra N. Sarkar, and Carolyn B. Coyne. Regulation of mitochondrial antiviral signaling (mavs) expression and signaling by the mitochondria-associated endoplasmic reticulum membrane (mam) protein gp78. Journal of Biological Chemistry, 289(3):1604–1616, January 2014. URL: http://dx.doi.org/10.1074/jbc.m113.520254, doi:10.1074/jbc.m113.520254. This article has 34 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m113.520254)

[5. (Koshiba2011Mitochondrial) Takumi Koshiba, Kai Yasukawa, Yusuke Yanagi, and Shun-ichiro Kawabata. Mitochondrial membrane potential is required for mavs-mediated antiviral signaling. Science Signaling, February 2011. URL: http://dx.doi.org/10.1126/scisignal.2001147, doi:10.1126/scisignal.2001147. This article has 195 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1126/scisignal.2001147)

[6. (Wang2022Reduced) Qian Wang, Zhenzhen Sun, Shihan Cao, Xiuli Lin, Mengying Wu, Yuanyuan Li, Jie Yin, Wei Zhou, Songming Huang, Aihua Zhang, Yue Zhang, Weiwei Xia, and Zhanjun Jia. Reduced immunity regulator mavs contributes to non-hypertrophic cardiac dysfunction by disturbing energy metabolism and mitochondrial homeostasis. Frontiers in Immunology, July 2022. URL: http://dx.doi.org/10.3389/fimmu.2022.919038, doi:10.3389/fimmu.2022.919038. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2022.919038)

[7. (Jiang2019Structural) Qiu-Xing Jiang. Structural variability in the rlr-mavs pathway and sensitive detection of viral rnas. Medicinal Chemistry, 15(5):443–458, July 2019. URL: http://dx.doi.org/10.2174/1573406415666181219101613, doi:10.2174/1573406415666181219101613. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.2174/1573406415666181219101613)

[8. (Buskiewicz2016Reactive) Iwona A. Buskiewicz, Theresa Montgomery, Elizabeth C. Yasewicz, Sally A. Huber, Michael P. Murphy, Richard C. Hartley, Ryan Kelly, Mary K. Crow, Andras Perl, Ralph C. Budd, and Andreas Koenig. Reactive oxygen species induce virus-independent mavs oligomerization in systemic lupus erythematosus. Science Signaling, November 2016. URL: http://dx.doi.org/10.1126/scisignal.aaf1933, doi:10.1126/scisignal.aaf1933. This article has 134 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1126/scisignal.aaf1933)

[9. (Baril2009MAVS) Martin Baril, Marie-Eve Racine, François Penin, and Daniel Lamarre. Mavs dimer is a crucial signaling component of innate immunity and the target of hepatitis c virus ns3/4a protease. Journal of Virology, 83(3):1299–1311, February 2009. URL: http://dx.doi.org/10.1128/jvi.01659-08, doi:10.1128/jvi.01659-08. This article has 118 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/jvi.01659-08)

[10. (Jacobs2013Mechanisms) Jana L. Jacobs and Carolyn B. Coyne. Mechanisms of mavs regulation at the mitochondrial membrane. Journal of Molecular Biology, 425(24):5009–5019, December 2013. URL: http://dx.doi.org/10.1016/j.jmb.2013.10.007, doi:10.1016/j.jmb.2013.10.007. This article has 155 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2013.10.007)

[11. (Ren2020Regulation) Zhihua Ren, Ting Ding, Zhicai Zuo, Zhiwen Xu, Junliang Deng, and Zhanyong Wei. Regulation of mavs expression and signaling function in the antiviral innate immune response. Frontiers in Immunology, May 2020. URL: http://dx.doi.org/10.3389/fimmu.2020.01030, doi:10.3389/fimmu.2020.01030. This article has 155 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2020.01030)

[12. (Chen2021An) Lifeng Chen, Jing Hou, Bingbing You, Feifei Song, Xinyi Tu, and Xiaodong Cheng. An analysis regarding the prognostic significance of mavs and its underlying biological mechanism in ovarian cancer. Frontiers in Cell and Developmental Biology, October 2021. URL: http://dx.doi.org/10.3389/fcell.2021.728061, doi:10.3389/fcell.2021.728061. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2021.728061)

[13. (Belgnaoui2011Orchestrating) S Mehdi Belgnaoui, Suzanne Paz, and John Hiscott. Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (mavs) adapter. Current Opinion in Immunology, 23(5):564–572, October 2011. URL: http://dx.doi.org/10.1016/j.coi.2011.08.001, doi:10.1016/j.coi.2011.08.001. This article has 189 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.coi.2011.08.001)